2,3-二氟-4-甲苯胺 | 886503-79-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氟-4-甲苯胺
• 中文别名: 2,3-二氟-4-甲基苯胺
• 英文名称: 2,3-difluoro-4-methylaniline
• CAS: 886503-79-3
• 化学式: C₇H₇F₂N
• mdl: MFCD06660321
• 分子量: 143.136
• InChiKey: HMDHQYKNBZEFTH-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  按规定使用和贮存的情况下，这些物质不会分解，并能避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2921430090

反应信息

• 作为反应物：
  描述：

  2,3-二氟-4-甲苯胺 在 sodium acetate 、 一氯化碘 作用下， 以 溶剂黄146 为溶剂， 反应 0.5h， 以72%的产率得到2,3-difluoro-6-iodo-4-methylaniline
  参考文献：
  名称：

  WO2007/36715

  摘要：

  公开号：
• 作为产物：
  描述：

  2,3-二氟-4-硝基甲苯 、 1,2-二氟-3-甲基-4-硝基苯 在 Raney nickel 肼 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 2,3-二氟-4-甲苯胺
  参考文献：
  名称：

  WO2007/36715

  摘要：

  公开号：

文献信息

• [EN] 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH BIND TO THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS<br/>[FR] DÉRIVÉS DE 6-AMINO-PYRIMIDINE-4-CARBOXAMIDE ET COMPOSÉS ASSOCIÉS QUI SE FIXENT AU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE (S1P) DANS LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
  申请人：SERONO LAB

  公开号：WO2009019167A1

  公开（公告）日：2009-02-12

  The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

  这项发明涉及式(I)的化合物：其中X、W、Q、R、R1和R2的含义如权利要求1所述。该化合物在治疗自身免疫性疾病（如多发性硬化症）方面是有用的。
• SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20160096841A1

  公开（公告）日：2016-04-07

  Provided herein are Aminopurine Compounds having the following structures: wherein R 1 , R 2 , and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如本文所定义，包含有效量氨基嘌呤化合物的组合物，以及用于治疗或预防癌症（例如黑色素瘤）的方法。
• Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them
  申请人：FRANCOTTE Pierre

  公开号：US20100009974A1

  公开（公告）日：2010-01-14

  Compounds of formula (I): wherein: R Cy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group, R 1 , R 2 , R 3 and R 4 , which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

  式（I）的化合物：其中：RCy表示未取代或取代的环烷基或环烷基烷基，R1、R2、R3和R4，可以相同也可以不同，每个代表氢或卤素原子或硝基团；氰基；羟基；烷氧基；烷基；未取代或取代的氨基团；羧基；烷氧羰基；芳基氧羰基；未取代或取代的氨基羰基。含有这些化合物的药物产品，可用于治疗或预防通过AMPA受体调节剂可治疗的疾病。
• Compounds which have activity at M1 receptor and their uses in medicine.
  申请人：Budzik Brian

  公开号：US20080058378A1

  公开（公告）日：2008-03-06

  Compounds of formula (I) and salts and solvates are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了式(I)的化合物及其盐和溶剂化物： 其中R4为氟，R5选自氢、卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基；R6选自卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C3-6环烷基、一种或多种氟原子取代的C3-6环烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基，Q为氢或C1-6烷基。这些化合物预计在治疗方面有用，例如在治疗精神障碍和认知障碍方面。
• Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
  申请人：Budzik Brian

  公开号：US20080255195A1

  公开（公告）日：2008-10-16

  Compounds of formula (I) and salts are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了化学式（I）和盐的化合物：其中R4为氟，R5从氢，卤素，氰基，C1-6烷基，C1-6烷基取代物，其中取代了一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代物中选择; R6从卤素，氰基，C1-6烷基，C1-6烷基取代物中选择，其中取代了一个或多个氟原子，C3-6环烷基，C3-6环烷基取代物中选择一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代物，Q为氢或C1-6烷基。预计这些化合物在治疗中会有用，例如在治疗精神障碍和认知障碍方面。